Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694593 | 1.00 | MAPK13 (0.47) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL1102295 | 0.85 | MEN1 (0.55) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL3669381 | 0.85 | MEN1 (0.55) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL4149590 | 0.79 | PRKCI (0.39) | PRKCICYP3A4CYP2D6NFKB1PRKD3 | |
| SCHEMBL4149597 | 0.79 | PRKCI (0.39) | PRKCICYP3A4CYP2D6NFKB1PRKD3 | |
| SCHEMBL3691847 | 0.79 | PRKCI (0.39) | PRKCICYP3A4CYP2D6NFKB1PRKD3 | |
| SCHEMBL10444851 | 0.77 | SMO (0.45) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL3695499 | 0.77 | SMO (0.55) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL3695501 | 0.77 | SMO (0.55) | MAPK13MAPK12MAPK11MAPK14KIT | |
| Tert-Butyl Formate SCHEMBL28793137 | 0.75 | MEN1 (0.43) | MAPK13MAPK12MAPK11MAPK14KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188283-B1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2188283-A1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | Amgen Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009035568-A1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | AMGEN INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | DPYD, CYP3A5, PNPO | MAPK13 3087/4885MAPK12 1628/4885MAPK11 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.